GB201522179D0 - Novel compounds - Google Patents

Novel compounds

Info

Publication number
GB201522179D0
GB201522179D0 GBGB1522179.9A GB201522179A GB201522179D0 GB 201522179 D0 GB201522179 D0 GB 201522179D0 GB 201522179 A GB201522179 A GB 201522179A GB 201522179 D0 GB201522179 D0 GB 201522179D0
Authority
GB
United Kingdom
Prior art keywords
novel compounds
novel
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB1522179.9A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Autifony Therapeutics Ltd
Original Assignee
Autifony Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Autifony Therapeutics Ltd filed Critical Autifony Therapeutics Ltd
Priority to GBGB1522179.9A priority Critical patent/GB201522179D0/en
Publication of GB201522179D0 publication Critical patent/GB201522179D0/en
Priority to PCT/GB2016/053958 priority patent/WO2017103604A1/en
Priority to BR112018012177A priority patent/BR112018012177A2/pt
Priority to JP2018531529A priority patent/JP7036725B2/ja
Priority to CN201680074553.9A priority patent/CN108430995A/zh
Priority to US16/061,557 priority patent/US20200377485A1/en
Priority to EP16816359.0A priority patent/EP3390394B1/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Anesthesiology (AREA)
  • Psychology (AREA)
  • Toxicology (AREA)
  • Rheumatology (AREA)
  • Addiction (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
GBGB1522179.9A 2015-12-16 2015-12-16 Novel compounds Ceased GB201522179D0 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
GBGB1522179.9A GB201522179D0 (en) 2015-12-16 2015-12-16 Novel compounds
PCT/GB2016/053958 WO2017103604A1 (en) 2015-12-16 2016-12-16 Hydantoin modulators of kv3 channels
BR112018012177A BR112018012177A2 (pt) 2015-12-16 2016-12-16 ?moduladores de hidantação de canais kv 3?
JP2018531529A JP7036725B2 (ja) 2015-12-16 2016-12-16 Kv3チャネルのヒダントインモジュレーター
CN201680074553.9A CN108430995A (zh) 2015-12-16 2016-12-16 新型化合物
US16/061,557 US20200377485A1 (en) 2015-12-16 2016-12-16 Hydantoin modulators of kv3 channels
EP16816359.0A EP3390394B1 (en) 2015-12-16 2016-12-16 Hydantoin modulators of kv3 channels

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1522179.9A GB201522179D0 (en) 2015-12-16 2015-12-16 Novel compounds

Publications (1)

Publication Number Publication Date
GB201522179D0 true GB201522179D0 (en) 2016-01-27

Family

ID=55274838

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB1522179.9A Ceased GB201522179D0 (en) 2015-12-16 2015-12-16 Novel compounds

Country Status (7)

Country Link
US (1) US20200377485A1 (cg-RX-API-DMAC7.html)
EP (1) EP3390394B1 (cg-RX-API-DMAC7.html)
JP (1) JP7036725B2 (cg-RX-API-DMAC7.html)
CN (1) CN108430995A (cg-RX-API-DMAC7.html)
BR (1) BR112018012177A2 (cg-RX-API-DMAC7.html)
GB (1) GB201522179D0 (cg-RX-API-DMAC7.html)
WO (1) WO2017103604A1 (cg-RX-API-DMAC7.html)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201521751D0 (en) 2015-12-10 2016-01-27 Autifony Therapeutics Ltd Novel uses
GB201613163D0 (en) 2016-07-29 2016-09-14 Autifony Therapeutics Ltd Novel compounds
US20200039970A1 (en) 2016-12-16 2020-02-06 Autifony Therapeutics Limited Hydantoin modulators of kv3 channels
PL3867247T3 (pl) 2018-10-16 2024-12-09 Autifony Therapeutics Limited Nowe związki
US12358901B2 (en) 2018-10-16 2025-07-15 Autifony Therapeutics Limited KV3 modulators
US20200131156A1 (en) * 2018-10-30 2020-04-30 H. Lundbeck A/S ARYLSULFONYLPYROLECARBOXAMIDE DERIVATIVES AS Kv3 POTASSIUM CHANNEL ACTIVATORS
US20220220095A1 (en) 2019-04-26 2022-07-14 H. Lundbeck A/S N-((HETEROARYL)METHYL)-1-TOSYL-1H-PYRAZOLE-3-CARBOXAMIDE DERIVATIVES AS Kv3 POTASSIUM CHANNEL ACTIVATORS FOR TREATING NEUROLOGICAL AND PSYCHIATRIC DISORDERS
CN113710318A (zh) 2019-04-26 2021-11-26 H.隆德贝克有限公司 作为Kv3钾通道激活剂的芳基磺酰基噻吩甲酰胺和芳基磺酰基呋喃甲酰胺
BR112022013339A2 (pt) 2020-02-06 2022-09-13 Autifony Therapeutics Ltd Moduladores de kv3
EP3901152A1 (en) * 2020-04-23 2021-10-27 F. Hoffmann-La Roche AG Kv3 enhancers for the treatment of cognitive disorders
CA3226856A1 (en) 2021-08-10 2023-02-16 Autifony Therapeutics Limited Potassium channel modulators
EP4630117A1 (en) 2022-12-06 2025-10-15 Autifony Therapeutics Limited Compounds for the treatment of centra nervous system disorders
WO2026093398A1 (en) 2024-10-29 2026-05-07 Autifony Therapeutics Limited Kv3 modulators for use in the treatment or prophylaxis of amyotrophic lateral sclerosis (als)

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6299383A (ja) * 1985-10-28 1987-05-08 Tokuyama Soda Co Ltd エ−テル化合物の製造方法
KR20050033663A (ko) * 2002-09-05 2005-04-12 메디비르 아베 비-뉴클레오시드 역전사효소 억제제
US20050080100A1 (en) * 2003-10-09 2005-04-14 Pfizer Inc Pyridylamino compounds and methods of use thereof
EP1845087A1 (en) * 2006-04-14 2007-10-17 Mutabilis SA Hydroxyphenyl derivatives and biological applications thereof
JP6112486B2 (ja) * 2010-04-27 2017-04-12 カルシメディカ,インク. 細胞内カルシウムを調節する化合物
KR101862375B1 (ko) * 2010-12-06 2018-05-29 오티포니 세라피틱스 리미티드 Kv3 억제제로서 유용한 하이단토인 유도체
WO2012170931A2 (en) * 2011-06-10 2012-12-13 Calcimedica, Inc. Compounds that modulate intracellular calcium
US9273054B2 (en) * 2011-07-27 2016-03-01 Glaxo Group Limited Substituted pyrimido[1,6-a]pyrimidines as Lp-PLA2 inhibitors
JP2015517563A (ja) * 2012-05-22 2015-06-22 アウトイフオンイ トヘラペウトイクス リミテッド Kv3阻害剤としてのヒダントイン誘導体
JP6226967B2 (ja) * 2012-06-06 2017-11-08 ヴァンダービルト ケミカルズ、エルエルシー 燃費効率がよい潤滑油
WO2013182851A1 (en) * 2012-06-06 2013-12-12 Autifony Therapeutics Limited Prophylaxis or treatment of diseases where a modulator of kv3.3 channels is required
WO2015031036A1 (en) * 2013-08-26 2015-03-05 Purdue Pharma L.P. Azaspiro[4.5] decane derivatives and use thereof

Also Published As

Publication number Publication date
US20200377485A1 (en) 2020-12-03
EP3390394B1 (en) 2022-05-25
CN108430995A (zh) 2018-08-21
JP7036725B2 (ja) 2022-03-15
BR112018012177A2 (pt) 2018-11-27
JP2019502696A (ja) 2019-01-31
EP3390394A1 (en) 2018-10-24
WO2017103604A1 (en) 2017-06-22

Similar Documents

Publication Publication Date Title
ZA201804739B (en) Novel compounds
IL255067A0 (en) new compounds
GB201516243D0 (en) Novel compounds
GB201522768D0 (en) Novel compounds
GB201521109D0 (en) Novel compounds
GB201506871D0 (en) Novel compounds
GB201501462D0 (en) Novel compounds
GB201510019D0 (en) Compounds
GB201504565D0 (en) Novel compounds
GB201514754D0 (en) Compounds
GB201508747D0 (en) Compounds
GB201514751D0 (en) Compounds
GB201510493D0 (en) Compounds
GB201508864D0 (en) Compounds
GB201502675D0 (en) Novel compounds
GB201503926D0 (en) Compounds
GB201501115D0 (en) Compounds
GB201508857D0 (en) Compounds
GB201521749D0 (en) Novel compounds
GB201521713D0 (en) Novel compounds
GB201516241D0 (en) Novel compounds
GB201512829D0 (en) Novel compounds
GB201512270D0 (en) Novel Compounds
GB201511842D0 (en) Novel compounds
GB201510191D0 (en) Novel compounds

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)